Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAY 3283142 in Hypertension
NCT05491642Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of BAY3283142 in hypertension (HTN) (3 arms), sponsored by Bayer. Primary endpoint: Number of participants with treatment-emergent adverse events. Started Sep 2022; status: completed.
02
Drugs
BAY3283142
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05491642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491642.